An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Hyaluronidase
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms PAVO
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 10 Nov 2017 Planned End Date changed from 31 Dec 2018 to 28 Feb 2019.
    • 10 Nov 2017 Planned primary completion date changed from 31 Jul 2018 to 12 Dec 2017.
    • 12 Oct 2017 Planned End Date changed from 14 Sep 2018 to 31 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top